The latest progress of breast cancer treatment at 2023 ESMO

Abstract

At 2023 Annual Meeting of European Society of Medical Oncology (ESMO), Several latest research achievements in the field of breast cancer were announced. For early-stage breast cancer, immune checkpoint inhibitor has not only continued to prove their value in the neoadjuvant treatment of triple-negative breast cancer (KEYNOTE-522 and NeoTRIP), but also shown their potential benefit in the neoadjuvant therapy of hormone receptor+/human epidermal growth factor receptor 2 (HER2)- breast cancer (KEYNOTE-756 and CheckMate 7FL). Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (as shown in the MONARCHE and NATALEE studies) have also solidified an important position in the adjuvant intensive treatment of hormone receptor+/HER2- breast cancer. In advanced breast cancer treatment, new endocrine therapy options and antibody-drug conjugate (T-DXd and Dato-DXd) have opened up new therapeutic opportunities for hormone receptor+/HER2- patients. Pooled analyses suggest that T-DXd has demonstrated outstanding efficacy in brain metastases of HER2+ breast cancer. Dato-DXd in combination with immunization and the new targeted antibody-drug conjugate HS-20089 produced promising efficacy in first-line treatment of and post-line triple-negative breast cancer, respectively.

Keywords

• |breast cancer treatment|immune checkpoint inhibitor|cyclin-dependent kinase 4/6 inhibitors|antibody-drug conjugate